134 Results for "

diffuse large B cell lymphoma

" in MedChemExpress (MCE) Product Catalog:
Products (134)

134 Results for "diffuse large B cell lymphoma" in MCE Product Catalog:

Cat. No.: HY-111781S
Synonyms: WS-413-d4
Research Areas:  

Cancer

Civorebrutinib-d4 (WS-413-d4) is the deuterated-labeled Civorebrutinib (HY-111781). Civorebrutinib (WS-413) is a selective, orally active BTK and TEC inhibitor with an IC50 of <100 nM for both targets. Civorebrutinib inhibits B cell activation. Civorebrutinib significantly suppresses the in vivo growth of diffuse large B-cell lymphoma cells. Civorebrutinib can be used for the research of diffuse large B-cell lymphoma.
loading...
    loading...
Cat. No.: HY-181296
CAS No.: 3093642-22-6
Research Areas:  

Cancer

PROTAC EZH2 Degrader-16 (compound 51) is a PROTAC protein degrader targeting EZH2 with an IC50 of 13.74 μM in SU-DHL-6 cells. PROTAC EZH2 Degrader-16 exerts antiproliferative activity against diffuse large B-cell lymphoma cells. PROTAC EZH2 Degrader-16 can be used for the research of diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-P992320

Target:  

CD47

Research Areas:  

Cancer

BAT-6004 is a monoclonal antibody that targets CD47 and is a CD47 inhibitor. BAT-6004 can be used in research on acute myeloid leukemia and diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-148640
CAS No.: 2253985-29-2
Research Areas:  

Cancer

WK500B is a potent and orally active BCL6 inhibitor with a KD of 1.61 μM. WK500B engages intracellular BCL6 and disrupts BCL6‑corepressor interactions to reactivate BCL6 target genes. WK500B exerts cytotoxicity against diffuse large B‑cell lymphoma cells and induces apoptosis and cell cycle arrest. WK500B suppresses germinal center formation in C57BL/6 mice and DLBCL tumor growth in SCID xenograft models without observable toxicity. WK500B can be used for the study of diffuse large B‑cell lymphoma (DLBCL) .
loading...
    loading...
Cat. No.: HY-188147
CAS No.: 2636048-41-2
Research Areas:  

Cancer

EZH2-IN-25 is an EZH2 inhibitor that inhibits the catalytic subunit of PRC2. EZH2-IN-25 can be used for the research of diffuse large B cell lymphoma .
loading...
    loading...
Cat. No.: HY-181547
CAS No.: 2963606-11-1
Target:  

Btk

Research Areas:  

Cancer

HBC-12551 is an orally active BTK inhibitor (IC50 in HEK293 cells: 1.31 nM for BTK; 2.18 nM for BTK C481S). HBC-12551 has antitumor activity against diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-P991899
Synonyms: LCB73 Antibody

Target:  

ADC Antibodies CD19

Research Areas:  

Cancer

IKS03 Antibody (LCB73 Antibody) is an anti-human CD19 antibody. IKS03 Antibody can generate antibody drug conjugate (ADC) (IKS03) with a pyrrolobenzodiazepine (PBD) dimer payload. IKS03 Antibody can be used for the study of diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) .
loading...
    loading...
Cat. No.: HY-111277
CAS No.: 856693-04-4
CEP-14513 is an ALK inhibitor with an IC50 of 4 nM. CEP-14513 also inhibits insulin receptor, VEGFR2, TIE2 and DLK kinases, but does not inhibit MET, IKKβ, or CDK1/2/5. CEP-14513 induces cancer cell apoptosis. CEP-14513 is applicable to research related to non-small cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, and diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-P992417

Target:  

CD20 Apoptosis

Research Areas:  

Cancer

MT-3724 is a CD20-targeted endotoxin B. MT-3724 binds to CD20, triggers receptor internalization, traffics to the endoplasmic reticulum, and induces permanent ribosomal inactivation to mediate cell killing. MT-3724 can inhibit protein synthesis and promote tumor cell apoptosis. MT-3724 can be used for the research of relapsed or refractory B-cell non-Hodgkin’s lymphomas and diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-181414
CAS No.: 3093642-26-0
Research Areas:  

Cancer

PROTAC EZH2 Degrader-45 (compound 61) is a PROTAC protein degrader targeting EZH2 with an IC50 of 22.97 μM in SU-DHL-6 cells. PROTAC EZH2 Degrader-45 can be used for the research of diffuse large b-cell lymphoma .
loading...
    loading...
Cat. No.: HY-181409
CAS No.: 3093642-40-8
Research Areas:  

Cancer

PROTAC EZH2 Degrader-40 (compound 56) is a PROTAC protein degrader targeting EZH2 with an IC50 of 15.35 μM against SU-DHL-6 cells. PROTAC EZH2 Degrader-40 can be used for the research of diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-181359
CAS No.: 3093642-31-7
Research Areas:  

Cancer

PROTAC EZH2 Degrader-30 (compound 67) is ais a PROTAC protein degrader targeting EZH2 with an IC50 of 6.22 μM against SU-DHL-6 cells. PROTAC EZH2 Degrader-30 can be used for the research of diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-180166
Target:  

BCL6

Research Areas:  

Cancer

BCL6-IN-12 (Compound 11e) is a BCL6 inhibitor with a Kd of 0.81 μM. BCL6-IN-12 binds to the BTB domain of BCL6. BCL6-IN-12 can be used in the research of diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-185428
Research Areas:  

Cancer

TRS-005 is an anti-CD20 ADC, formed by conjugating an anti-CD20 monoclonal antibody to MMAE (HY-15162) via a Val-Cit (HY-140014) linker. TRS-005 targets CD20-positive tumor cells and delivers MMAE into cells through receptor-mediated endocytosis. TRS-005 can be used for research on relapsed/refractory B-cell non-Hodgkin lymphoma (specifically diffuse large B-cell lymphoma) .
loading...
    loading...
Cat. No.: HY-181833
CAS No.: 3109464-35-6
Target:  

ADC Payloads PI3K

Research Areas:  

Cancer

PI3K/PIKK-IN-1 is a PI3K and PIKK inhibitor that serves as a payload for antibody-drug conjugates (ADC) to prepare ADC. PI3K/PIKK-IN-1 is applicable to research related to breast cancer, multiple myeloma, Burkitt lymphoma, diffuse large B-cell lymphoma, and non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-182706
CAS No.: 95455-02-0
Research Areas:  

Cancer

NSC 373981 is a CARD11 G4 stabilizer. NSC 373981 stabilizes the CARD11 G4 structure and inhibits CARD11 transcription in cells. NSC 373981 also inhibits BCL2 and MYC. NSC 373981 suppresses the transcription of KRAS and TERT. NSC 373981 exhibits anticancer activity against diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-181084
CAS No.: 3039500-55-2
PROTAC BCL6/GSPT1 Degrader-1 is a dual-target PROTAC degrader that targets BCL6 and GSPT1. PROTAC BCL6/GSPT1 Degrader-1 inhibits cell proliferation, promotes DNA damage, and induces cell cycle arrest and apoptosis in diffuse large B-cell lymphoma. PROTAC BCL6/GSPT1 Degrader-1 can be used for research on tumors such as lymphoma .
loading...
    loading...
Cat. No.: HY-158813
CAS No.: 2364639-42-7
Research Areas:  

Cancer

S-Geranylgeranyl-L-glutathione is a P2RY8 inhibitor and intercellular signaling molecule that exists endogenously in human bone marrow interstitial fluid. S-Geranylgeranyl-L-glutathione promotes the internalization of P2RY8 and antagonizes chemokine-induced activation of pAkt. S-Geranylgeranyl-L-glutathione negatively regulates the migration of B cells and T cells to the bone marrow, inhibits chemokine-mediated migration of germinal center B cells and follicular helper T cells, participates in lymphocyte guidance regulation, and modulates the germinal center response process. S-Geranylgeranyl-L-glutathione can be used in research related to diffuse large B-cell lymphoma and Burkitt lymphoma .
loading...
    loading...
Cat. No.: HY-184007
CAS No.: 3121287-19-9
Target:  

PROTACs BCL6

Research Areas:  

Cancer

PROTAC BCL6 Degrader-4 is a potent PROTAC BCL6 degrader. PROTAC BCL6 Degrader-4 recruits CRBN E3 ligase machinery to promote ubiquitination and proteasomal degradation of BCL6. PROTAC BCL6 Degrader-4 can be used for the research of diffuse large B-cell lymphoma and related hematological malignancies .
loading...
    loading...
Cat. No.: HY-P991839

Target:  

CD19

Research Areas:  

Cancer

Anti-CD19 Antibody (FMC63) is an antibody that binds to CD19, with a human Kd value ranging from 0.42 nM to 149 nM. Anti-CD19 Antibody (FMC63) mediates tumor cell killing, cytokine secretion, stable CAR expression, T cell activation and memory differentiation. Anti-CD19 Antibody (FMC63) fails to eliminate lymphoma cells carrying CD19 point mutations or co-expressing FMC63-CAR19, induces higher levels of activation-induced cell death, and reduces cell persistence. Anti-CD19 Antibody (FMC63) can be used in research related to B-cell non-Hodgkin's lymphoma, B-cell acute lymphoblastic leukemia, relapsed or refractory diffuse large B-cell lymphoma, etc .
loading...
    loading...